Article By:
The Fly
Monday, January 22, 2018 7:42 AM EDT
Sanofi and Bioverativ have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6B.